Stella Pharma (TSE:4888) Total Long-Term Assets: 円133.6 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4888 Stella Pharma Corp TSE:4888
77 GF Score
Price 円340.00
GF Value 円369.89
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Stella Pharma Total Long-Term Assets?

Stella Pharma TSE:4888 +0.29% 77 Total Long-Term Assets is 円133.6 Mil as of Mar. 2026. GuruFocus rates TSE:4888 with a GF Score™ of 77/100 and a GF Value™ of 円369.89 (Fairly Valued). The stock has 4 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Stella Pharma's Total Long-Term Assets for the quarter that ended in Mar. 2026 was 円133.6 Mil.

Stella Pharma Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Stella Pharma's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stella Pharma Total Long-Term Assets Chart

Stella Pharma Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Long-Term Assets
Get a 7-Day Free Trial 543.46 536.32 191.33 173.63 133.57

Stella Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 173.63 161.14 150.02 139.56 133.57
TSE:4888
77GF Score
Stella Pharma Corp TSE:4888
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stella Pharma Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of 円133.6 Mil mean?
Stella Pharma (TSE:4888) has a Total Long-Term Assets of 円133.6 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Stella Pharma and its competitors.
Is Stella Pharma's Total Long-Term Assets too high?
Stella Pharma's current Total Long-Term Assets is 円133.6 Mil. Overall, Stella Pharma has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's Total Long-Term Assets compare to VRTX and REGN?
Stella Pharma's Total Long-Term Assets of 円133.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Stella Pharma and its competitors. Stella Pharma's current Total Long-Term Assets is 円133.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Fairly Valued. The stock's GF Value™ is 円369.89, compared to a current price of 円340.00 — trading 8.1% below its estimated fair value. The current Total Long-Term Assets is 円133.6 Mil. Stella Pharma's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current Total Long-Term Assets is 円133.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stella Pharma (TSE:4888) Overvalued in 2026?

Based on GuruFocus' analysis, Stella Pharma stock appears to be undervalued. The current stock price of 円340.00 is trading 8.1% below its estimated GF Value™ of 円369.89. GuruFocus considers Stella Pharma to be Fairly Valued.

Key valuation signals for TSE:4888:

  • Total Long-Term Assets: 円133.6 Mil
  • GF Value™: 円369.89 vs. price of 円340.00 (8.1% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stella Pharma Business Description

Address 3-2-7 Korai-bashi, Chuo-ku, Osaka Prefecture, Osaka, JPN, 541-0043
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
77GF Score

Get the complete analysis for TSE:4888

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円340.00
Price
円369.89
GF Value